Retatrutide
Reta · Triple-G · LY3437943
An investigational triple receptor agonist (GIP, GLP-1 and glucagon) conjugated to a fatty-diacid for albumin binding, studied in trials for obesity and metabolic disease. Its half-life supports once-weekly administration.
Tracking and educational reference only, on values you enter or import yourself. Not medical advice or a dosing recommendation.
Regulatory status
Investigational
This substance is under study in humans, typically under a regulatory authorization such as an Investigational New Drug application. Investigational describes a stage of research and nothing more: it does not mean approval is coming, and it does not indicate that effectiveness has been established.
A regulatory status describes paperwork, not safety. An approved compound can still be wrong for a given person, and an unapproved one is neither thereby dangerous nor thereby fine.
Half-life
~6 days, subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Supplied lyophilized; store cool, reconstitute before use, then refrigerate and protect from light.
References
- Jastreboff et al., NEJM 2023 (phase 2 obesity)
- Nature Medicine 2024 (phase 2a MASLD)
Read the source
Common questions
Retatrutide, answered plainly.
01What is Retatrutide?+
An investigational triple receptor agonist (GIP, GLP-1 and glucagon) conjugated to a fatty-diacid for albumin binding, studied in trials for obesity and metabolic disease. Its half-life supports once-weekly administration. It is also referred to as Reta, Triple-G, LY3437943. It is listed here under GLP-1 / Metabolic as educational reference, which is not a recommendation to use it.
02Is Retatrutide FDA approved?+
Investigational. This substance is under study in humans, typically under a regulatory authorization such as an Investigational New Drug application. Investigational describes a stage of research and nothing more: it does not mean approval is coming, and it does not indicate that effectiveness has been established.
03What is the half-life of Retatrutide?+
~6 days, subcutaneous. A half-life is an educational pharmacology figure describing how long the body takes to clear half of a substance. It is not a schedule and does not imply one.
04How is Retatrutide stored and handled?+
Supplied lyophilized; store cool, reconstitute before use, then refrigerate and protect from light. Storage conditions come from a manufacturer's own label where one exists, and a compound with no approved label has no agency-reviewed handling instructions at all.
05What vial strengths of Retatrutide are commonly sold?+
Commonly listed vial strengths are 5, 10, 15, 20, 30 mg. A vial strength is a market fact about how a product is packaged. It is not a dose, and it says nothing about how much of anything belongs in any person.
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.